Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PACE CART19 in Relapsed/Refractory CD19+ Leukemia and Lymphoma
NCT05037669Phase 1Withdrawn
- Sponsor
- University of Pennsylvania
- Start
- Jul 2022
- Primary completion
- Jan 2025
- Modality
- Gene Silencing, CRISPR-Cas9, CAR-T Cells
01
Overview
Phase 1, open-label trial of PACE CART19 in acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL) (2 cohorts), sponsored by University of Pennsylvania. Primary endpoints: Frequency and severity of adverse events at 28 days, Time from consent to first PACE CART19 infusion at 12 months and 1 more. Planned start Jul 2022; status: withdrawn.
02
Drugs
PACE CART19
03
Conditions
acute lymphoblastic leukemia (ALL)chronic lymphocytic leukemia (CLL)non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT05037669.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05037669.